Mounjaro and Appendicitis: Separating Signal from Noise

Step 1: Check what the trial data and prescribing information say

Across the SURMOUNT clinical programme (which enrolled thousands of adults with obesity across multiple countries) appendicitis was not identified as a treatment-related adverse event in the published results for tirzepatide. The SURMOUNT-1 trial, reported in the New England Journal of Medicine, recorded GI side effects as the most common class of events, led by nausea, vomiting, diarrhoea, and constipation. Appendicitis did not feature among them. The UK-authorised SmPC for Mounjaro, accessible via the electronic Medicines Compendium, lists the recognised adverse reactions in detail, and appendicitis is absent from that list. That absence matters. It means the regulatory review of the clinical trial dataset did not find an elevated rate of appendicitis in people taking tirzepatide compared with placebo. If a signal had emerged, it would appear there, as a Black Triangle product under additional MHRA monitoring. So the direct answer to "can Mounjaro cause appendicitis" is: current evidence does not support that conclusion, and you can read more about what happens with Mounjaro in the UK, including how the medicine is monitored and dispensed under the current authorisation.

Step 2: Understand why abdominal pain on Mounjaro can be confusing

Tirzepatide works on two gut-hormone pathways simultaneously, slowing how quickly the stomach empties and altering the rhythm of the digestive tract. For many people, this produces predictable GI effects, nausea after starting or increasing the dose, occasional cramping, loose stools, or a heavy sensation after eating. These usually peak in the first few days after a dose and ease as the body adjusts. The difficulty is that this background of gut discomfort can, in principle, make it harder to recognise pain that originates elsewhere in the abdomen. Appendicitis classically presents with pain that starts centrally and migrates to the lower right, accompanied by fever, loss of appetite, and nausea, symptoms that overlap superficially with GLP-1-related GI effects. This is not a reason to panic, but it is a reason to pay attention. If abdominal pain is worsening, localised, or accompanied by fever, the right move is a same-day call to 111 or your GP, not a wait-and-see approach. For broader context on how tirzepatide affects the gut, our Mounjaro and gastritis page covers the related question of stomach inflammation in more detail.

Step 3: Know which abdominal emergencies the MHRA does flag for GLP-1 medicines

In January 2026, the MHRA issued a Drug Safety Update for the GLP-1 class (including tirzepatide) focused on acute pancreatitis. The specific warning sign is severe or persistent stomach pain that may radiate to the back, with or without vomiting. This is the abdominal emergency the regulator wants patients and clinicians to act on urgently. Gallbladder problems, including gallstones and cholecystitis, are also noted in the SmPC as less common adverse events. Neither pancreatitis nor gallbladder disease is appendicitis, but all three can cause significant abdominal pain and all three require medical assessment rather than self-management. If you are unsure what is causing abdominal pain while taking Mounjaro, tell the clinician you are on tirzepatide: it helps them interpret your symptoms accurately. You can report any suspected adverse reactions, including abdominal symptoms you think may be linked to Mounjaro, through the MHRA Yellow Card scheme. Our page on Mounjaro and colitis addresses another GI concern patients sometimes raise alongside questions about tirzepatide and appendicitis.

Step 4: What to do if you have concerns while on treatment

Practical guidance here is straightforward. Mild GI discomfort (the kind that surfaces after the weekly injection and fades over a day or two) is expected and not a reason to stop treatment without speaking to your prescriber first. Symptoms that should prompt same-day contact with a clinician include: pain that is worsening rather than settling, pain that has a specific location (especially lower right abdomen), fever alongside abdominal pain, vomiting that prevents you keeping fluids down, or any pain severe enough that you would ordinarily call 111. If in doubt, call 111. Do not wait until your next scheduled review. Patients who come to nume with questions about abdominal symptoms during treatment can reach our aftercare team seven days a week, a genuine clinical contact, not a helpdesk script. That aftercare is built into what you pay for; there are no add-on charges for raising a concern mid-treatment. If you are considering whether tirzepatide is right for you in the first place, the tirzepatide overview covers the full picture of how the medicine works, what the trial evidence shows, and what the clinical assessment involves. For questions about what happens when Mounjaro first starts working in the body, including early gut effects, our page on how quickly Mounjaro takes effect is a useful companion. And if pricing is a consideration alongside the clinical decision, the cost page sets out what private treatment typically includes. When you are ready to discuss suitability with a prescriber, check your eligibility through a free consultation, reviewed the same day by a real clinician.